223 related articles for article (PubMed ID: 26048374)
1. Targeting Wnt pathway in mantle cell lymphoma-initiating cells.
Mathur R; Sehgal L; Braun FK; Berkova Z; Romaguerra J; Wang M; Rodriguez MA; Fayad L; Neelapu SS; Samaniego F
J Hematol Oncol; 2015 Jun; 8():63. PubMed ID: 26048374
[TBL] [Abstract][Full Text] [Related]
2. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.
Jung HJ; Chen Z; McCarty N
Leuk Lymphoma; 2011 Jun; 52(6):1066-79. PubMed ID: 21599592
[TBL] [Abstract][Full Text] [Related]
3. Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma.
Emruli VK; Olsson R; Ek F; Ek S
BMC Cancer; 2016 Jul; 16():493. PubMed ID: 27430213
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
[TBL] [Abstract][Full Text] [Related]
5. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
6. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
7. The Wnt signaling pathway and mitotic regulators in the initiation and evolution of mantle cell lymphoma: Gene expression analysis.
Kimura Y; Arakawa F; Kiyasu J; Miyoshi H; Yoshida M; Ichikawa A; Niino D; Sugita Y; Okamura T; Doi A; Yasuda K; Tashiro K; Kuhara S; Ohshima K
Int J Oncol; 2013 Aug; 43(2):457-68. PubMed ID: 23760751
[TBL] [Abstract][Full Text] [Related]
8. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
9. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
10. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.
Chen Z; Ayala P; Wang M; Fayad L; Katz RL; Romaguera J; Caraway N; Neelapu SS; Kwak LW; Simmons PJ; McCarty N
Stem Cell Res; 2010 Nov; 5(3):212-25. PubMed ID: 20851072
[TBL] [Abstract][Full Text] [Related]
11. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
12. The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
Li XY; Li Y; Zhang L; Liu X; Feng L; Wang X
Oncol Rep; 2017 Nov; 38(5):3114-3120. PubMed ID: 28901456
[TBL] [Abstract][Full Text] [Related]
13. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.
Kuo PY; Leshchenko VV; Fazzari MJ; Perumal D; Gellen T; He T; Iqbal J; Baumgartner-Wennerholm S; Nygren L; Zhang F; Zhang W; Suh KS; Goy A; Yang DT; Chan WC; Kahl BS; Verma AK; Gascoyne RD; Kimby E; Sander B; Ye BH; Melnick AM; Parekh S
Oncogene; 2015 Mar; 34(10):1231-40. PubMed ID: 24681958
[TBL] [Abstract][Full Text] [Related]
14. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.
Luanpitpong S; Poohadsuan J; Samart P; Kiratipaiboon C; Rojanasakul Y; Issaragrisil S
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3739-3753. PubMed ID: 30251692
[TBL] [Abstract][Full Text] [Related]
17. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.
Hegde GV; Nordgren TM; Munger CM; Mittal AK; Bierman PJ; Weisenburger DD; Vose JM; Sharp JG; Joshi SS
Int J Cancer; 2012 Dec; 131(12):2951-60. PubMed ID: 22511234
[TBL] [Abstract][Full Text] [Related]
18. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
